[1]
Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988; 3(3): 255-66.
[http://dx.doi.org/10.1097/00004850-198807000-00007] [PMID: 3153713]
[http://dx.doi.org/10.1097/00004850-198807000-00007] [PMID: 3153713]
[2]
Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M. Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial. Biol Psychiatry 2015; 78(1): 10-8.
[http://dx.doi.org/10.1016/j.biopsych.2014.11.016]
[http://dx.doi.org/10.1016/j.biopsych.2014.11.016]
[3]
Zorumski CF, Nagele P, Mennerick S, Conway CR. Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy. Front Psychiatry 2015; 6: 172.
[http://dx.doi.org/10.3389/fpsyt.2015.00172]
[http://dx.doi.org/10.3389/fpsyt.2015.00172]
[4]
Das RK, Tamman A, Nikolova V, et al. Nitrous oxide speeds the reduction of distressing intrusive memories in an experimental model of psychological trauma. Psychol Med 2016; 46(8): 1749-59.
[http://dx.doi.org/10.1017/S003329171600026X] [PMID: 26937942]
[http://dx.doi.org/10.1017/S003329171600026X] [PMID: 26937942]
[5]
Walsh K, Das RK, Kamboj SK. The subjective response to nitrous oxide is a potential pharmaco-endophenotype for alcohol use disorder: A preliminary study with heavy drinkers. Int J Neuropsychopharmacol 2016; 20(4): pyw063.
[http://dx.doi.org/10.1093/ijnp/pyw063] [PMID: 27401180]
[http://dx.doi.org/10.1093/ijnp/pyw063] [PMID: 27401180]
[6]
Nagele P, Brown F, Yohanna D. Prolonged remission of major depressive disorder after single nitrous oxide inhalation treatment. Front Psychiatry 2020; 11: 692.
[http://dx.doi.org/10.3389/fpsyt.2020.00692]
[http://dx.doi.org/10.3389/fpsyt.2020.00692]
[7]
Varias V, van Roessel P, Parsiani M, et al. Does nitrous oxide help veterans with posttraumatic stress disorder? A case series. J Clin Psychiat 2020; 81(12): 20l13393.
[http://dx.doi.org/10.4088/JCP.20l13393]
[http://dx.doi.org/10.4088/JCP.20l13393]
[8]
Desmidt T, Gissot V, Dujardin PA, et al. A case of sustained antidepressant effects and large changes in the brain with a single brief exposure to nitrous oxide. Am J Geriatr Psychiatry 2021; 29(12): 1298-300.
[http://dx.doi.org/10.1016/j.jagp.2021.01.138] [PMID: 33612348]
[http://dx.doi.org/10.1016/j.jagp.2021.01.138] [PMID: 33612348]
[9]
Izumi Y, Hsu FF, Conway CR, Nagele P, Mennerick SJ, Zorumski CF. Nitrous oxide, a rapid antidepressant, has ketamine-like effects on excitatory transmission in the adult hippocampus. Biol Psychiatry 2022; 3223(22): 01365-8.
[10]
Williams NR, Heifets BD, Blasey C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175(12): 1205-15.
[http://dx.doi.org/10.1176/appi.ajp.2018.18020138] [PMID: 30153752]
[http://dx.doi.org/10.1176/appi.ajp.2018.18020138] [PMID: 30153752]
[11]
Klein ME, Chandra J, Sheriff S, Malinow R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc Natl Acad Sci USA 2020; 117(5): 2656-62.
[http://dx.doi.org/10.1073/pnas.1916570117] [PMID: 31941713]
[http://dx.doi.org/10.1073/pnas.1916570117] [PMID: 31941713]
[12]
A Gillman M. Opioid activity of nitrous oxide and ketamine. Acta Scientific Dental Scienecs 2019; 3(10): 41-2.
[http://dx.doi.org/10.31080/ASDS.2019.03.0642]
[http://dx.doi.org/10.31080/ASDS.2019.03.0642]
[13]
Gillman MA. Analgesic (sub anesthetic) nitrous oxide interacts with the endogenous opiod system: A review of the evidence. Life Sci 1986; 39(14): 1209-21.
[http://dx.doi.org/10.1016/0024-3205(86)90181-5] [PMID: 3020325]
[http://dx.doi.org/10.1016/0024-3205(86)90181-5] [PMID: 3020325]
[14]
Gillman MA, Lichtigfeld FJ. Opioid properties of psychotropic analgesic nitrous oxide (laughing gas). Perspect Biol Med 1994; 38(1): 125-38.
[http://dx.doi.org/10.1353/pbm.1994.0026] [PMID: 7997355]
[http://dx.doi.org/10.1353/pbm.1994.0026] [PMID: 7997355]
[15]
Gillman MA. Analgesic nitrous oxide should join the opioid family after almost two centuries. S Afr J Sci 1993; 89: 25-7.
[16]
Lichtigfeld FJ, Gillman MA. The treatment of alcoholic withdrawal states with oxygen and nitrous oxide. S Afr Med J 1982; 61(10): 349-51.
[PMID: 7064002]
[PMID: 7064002]
[17]
Gillman MA, Matussek N, Lichtigfeld FJ. Effect of nitrous oxide on depressive patients and volunteersBiological psychiatry, higher nervous activity. Berlin: Springer 1985; pp. 397-4031.
[http://dx.doi.org/10.1007/978-1-4684-8329-1_58]
[http://dx.doi.org/10.1007/978-1-4684-8329-1_58]
[18]
Gillman MA, Footerman DS. The need for a clearer distinction between anesthesia and analgesia in relation to the opiate system. Anesthesiology 1981; 54(6): 524.
[http://dx.doi.org/10.1097/00000542-198106000-00018] [PMID: 7235283]
[http://dx.doi.org/10.1097/00000542-198106000-00018] [PMID: 7235283]
[19]
Gillman MA. What is better for psychiatry: Titrated or fixed concentrations of nitrous oxide? Front Psychiatry 2022; 13: 773190.
[http://dx.doi.org/10.3389/fpsyt.2022.773190] [PMID: 36072452]
[http://dx.doi.org/10.3389/fpsyt.2022.773190] [PMID: 36072452]
[20]
Jevtović-Todorović V, Todorovć SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4(4): 460-3.
[http://dx.doi.org/10.1038/nm0498-460] [PMID: 9546794]
[http://dx.doi.org/10.1038/nm0498-460] [PMID: 9546794]
[22]
Nagele P, Palanca BJ, Gott B, et al. A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med 2021; 13(597): eabe1376.
[http://dx.doi.org/10.1126/scitranslmed.abe1376] [PMID: 34108247]
[http://dx.doi.org/10.1126/scitranslmed.abe1376] [PMID: 34108247]